Specialty drugs more than doubled as a share of retail fills for the overall U.S. population between 2010 and 2017, according to a study using various sources and published in Health Affairs, growing from 1% to 2.3%.

Despite representing a small percentage of overall prescriptions, spending on these drugs accounted for approximately half of the country’s total spending on retail, mail-order and provider-administered drugs in 2018; however, the study noted that the cost of these drugs are difficult to track due to the use of manufacturer rebates.

Net spending was divided at 31.5% for all retail and mail-order drugs for Medicare Part D, 37.8% for Medicaid and 43.6% of private drug spending.

Related News Articles

Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…